In an infrequently held (last one was 2007) conference for industry analysts yesterday, BMS CEO Lamberto Andreotti presented the pipeline overview. BMS has 60 compounds in development - about 6 times as many as have been introduced in the last 7 years. Late stage performers include ipilimumab (skin cancer), brivanib (liver disease), XL-184 (cancer agent), apixaban (blood thinner), dapagliflozin (diabetes), and belatacept (organ rejection). Of these BMS expects 5 of these to make it to commercial launch by 2012 to help with the nasty consequences of Plavix coming off patent. See more and full BMS release by going to Fierce Biotech.
Posted by Bruce Lehr March 5th.